NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial (vol 20, pg 1148, 2019)

Bonvalot S.; Rutkowski P. L.; Thariat J.

首页> 外文期刊>The lancet oncology >NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial (vol 20, pg 1148, 2019)

【24h】

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial (vol 20, pg 1148, 2019)

机译：NBTXR3是一流的氧化铪纳米铪纳米胺，加上放射疗法与放疗患者在局部先进的软组织Sarcoma患者中（ACT.IN.SARC）：多期，第2-3期，随机，受控试验（VOL 20 ，pg 1148,2019）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2019年第9期|共1页
作者
Bonvalot S.; Rutkowski P. L.; Thariat J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial (vol 20, pg 1148, 2019) [J] . Bonvalot S., Rutkowski P. L., Thariat J. The lancet oncology . 2019,第9期

机译：NBTXR3是一流的氧化铪纳米铪纳米胺，加上放射疗法与放疗患者在局部先进的软组织Sarcoma患者中（ACT.IN.SARC）：多期，第2-3期，随机，受控试验（VOL 20 ，pg 1148,2019）
2. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): a multicentre, phase 2-3, randomised, controlled trial [J] . Bonvalot Sylvie, Rutkowski Piotr L., Thariat Juliette, The lancet oncology . 2019,第8期

机译：第一类Roodtionhancer铪氧化物纳米粒子，加上放射疗法对局部先进的软组织Sarcoma患者的放射疗法（ACT。SARC）：多期，第2-3期，随机，受控试验
3. Act.in.Sarc: An International Randomized Phase III Trial Evaluating Efficacy and Safety of First-in-Class NBTXR3 Hafnium Oxide Nanoparticles Activated By Preoperative Radiotherapy in Locally Advanced Soft Tissue Sarcoma [J] . S. Bonvalot, P. Rutkowski, J.O. Thariat, International Journal of Radiation Oncology, Biology, Physics . 2018,第5期

机译：ACT.IN.SARC：通过术前放疗术语激活的术语中，在局部先进的软组织SARCOMA中激活的一类IID阶段III试验评估一阶级NBTXR3氧化铪纳米粒子的疗效和安全性
4. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial [O] . Stephen J Falk, David J Girling, Roger J White, 2002

机译：不可切除的局部晚期非小细胞肺癌患者的立即或延迟姑息性胸腔放疗治疗：胸腔症状轻微：随机对照试验
5. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial [O] . Giralt Jordi, Trigo Jose, Nuyts Sandra, 2015

机译：帕尼单抗联合放疗与放化疗联合治疗未切除的局部晚期头颈部鳞状细胞癌（CONCERT-2）：一项随机，对照，开放标签的2期试验

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial (vol 20, pg 1148, 2019)

著录项

相似文献

相关主题

期刊订阅